Listing & Compliance Notices

Canoo Inc. received a nasdaq delisting notice notice regarding other.

“January 22, 2025, the Company received a letter from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that the Staff has determined that the Company’s securities will be delisted from Nasdaq based on the following factors: • The Company’s filing for protection under Chapter 7 of the U.S. Bankruptcy Code on January 17, 2025 (the “Filing”) and public interest concerns raised by it; • Concerns regarding the residual equity interest of the existing listed securities holders; and • Concerns about the Company’s ability”

Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 23, 2025, Onconetix, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.00001 per share (“Common Stock”), from November 25, 2024 to January 10, 2025, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice has no immediate effect on the continued li”

Lyell Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar da”

Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).

“January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee requirements as set forth in Nasdaq Listing Rule 5605. Nasdaq Listing Rule 5605 requires, among other things, that each listed company must have an audit committee comprised of at least three members, each of whom must meet certain independence and other qualifications as set forth in such rule. As a result of the previously reported resignation of Adam M. Koppel, M.D., Ph.D. f”

Zoomcar Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).

“The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that for the previous 30 consecutive business days, the market value of publicly held shares for the Company was below the minimum $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Rule”). Under Nasdaq Listing Rule 5810(c)(3)(D), the Company was provided a period of 180 calendar days (or until January 21, 2025) to regain compliance with the MVPHS Rule. The Company did not regain compliance with the MVPHS Rule within the 180-day compliance period. In a”

Technology & Telecommunication Acquisition Corp received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 23, 2025 and (iii) a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2 , a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by January 14, 2025, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities”

Damon Inc. received a nasdaq deficiency notice notice regarding minimum bid price.

“January 22, 2025, Damon Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the”

Technology & Telecommunication Acquisition Corp received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 16, 2025, Technology & Telecommunication Acquisition Corporation (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that, pursuant to Nasdaq”

Zoomcar Holdings, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).

“January 23, 2025, the Company received a further notice from the Staff, notifying the Company that its failure to regain compliance with the MVPHS Rule serves as an additional basis for delisting the Company’s securities”

Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee.

“January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee”

Lyell Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec”

Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 23, 2025, Onconetix, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s commo”

Canoo Inc. received a nasdaq delisting notice notice regarding other.

“January 22, 2025, the Company received a letter from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that the Staff has determined that th”

PAVmed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 23, 2025, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through J”

Hyzon Motors Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b)).

“January 23, 2025, Hyzon Motors Inc. (the “Company”) received a determination letter (the “Delisting Notification”) from The Nasdaq Stock Market (“Nasdaq”) stating that the Nasdaq staff (“Staff”) determined, in accordance with Listing Rules 5101 and 5110(b) and Nasdaq Listing Rule IM 5101-1, that the Company’s securities, including its Class A common stock, par value $0.0001 per share, and public warrants, will be delisted from Nasdaq. The Delisting Notification indicates that the Staff’s determination was based on, among other items, the Company’s previously announced Plan of Dissolution to wh”

Lazydays Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A), 5810(c)(3)(H)).

“Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Requiremen t”). The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market or on the trading of the Common Stock, which continues to trade under the symbol “GORV”. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until July 22, 2025 (the “ Compliance Date ”), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Common Stock closes at $1.00 or more for a min”

IMAC Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

““Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1) (the “Equity Rule”), and on July 17, 2024, the Company was notified by Nasdaq that it regained compliance with the minimum stockholders’ equity requirement and was subjected to a one-year “Panel Monitor” as defined by Nasdaq Listing Rule 5815(d)(4)(B). On January 21, 2025, the Company rec”

RF Acquisition Corp. received a nasdaq hearing update notice regarding other (rules 5450(a)(2), 5405).

“January 21, 2025, the Company received a written notice from Nasdaq stating that, based on the information presented at the hearing, the Panel has determined to grant the Company’s request for continued listing on Nasdaq, subject to the Company demonstrating compliance with Listing Rule 5405 on or before March 23, 2025.”

Cycurion, Inc. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 23, 2025 and (iii) a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by January 11, 2025, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities a”

Cycurion, Inc. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 16, 2025, Western Acquisition Ventures Corp. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that, pursuant to Nasdaq Listing Rule IM-510”

Lazydays Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 23, 2025, Lazydays Holdings, Inc. (the “ Company ”) received written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that for t”

BOLLINGER INNOVATIONS, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“January 15, 2025, Mullen Automotive Inc. (the “ Company ”) received an expected notice (the “ Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2024 (the “ Form 10-K ”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Listing Rule ”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “ SEC ”). The Notice has no immed”

374Water Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 15, 2025, 374Water Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its c”

374Water Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 15, 2025, 374Water Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the l”

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq hearing update notice regarding market value.

“January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On the same day, the Company received a letter from Nasdaq notifying the Company that, among other things, (i) the Panel hearing will be held on February 25, 2025, and (ii) the hearing request submitted by the Company has stayed the delisting action pending a final written decision by the Panel. At the hearing, the Company will demonstrate its ability to regain compliance with the deficiencies cited by the Staff, as well as its ability to sustain long-term c”

Pluri Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“epartment of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital”

CIMG Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 14, 2025, CIMG Inc. (the “Company”) received a notification letter (the “Minimum Bid Price Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for”

T Stamp Inc received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 14, 2025, T Stamp Inc. (the “ Company ”) received a letter from The Nasdaq Stock Market LLC (“ Nasdaq ”), which stated that the Company no longer complies with Nasdaq’s continued listing rules due to the Company not having held an annual meeting of its stockholders within twelve months of the end of the Company’s fiscal year end, as required pursuant to Nasdaq Listing Rule 5620(a). In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an exception of up t”

NOCERA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“isting Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an”

GAN Ltd received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“January 14, 2025, GAN Limited (the “Company” ), received a written notice from The Nasdaq Stock Market LLC ( “Nasdaq” ) notifying the Company that it was not in compliance with the rules for continued listing as set forth in Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) due to the Company not having held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. The Company has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company may be granted an exception of up to 180 calendar days from the fiscal year e”

Healthcare Triangle, Inc. received a nasdaq noncompliance notice notice regarding shareholders (rules 5620).

“January 14, 2025, Healthcare Triangle, Inc. (the “ Company ”), received a letter from Nasdaq (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rules since it has not yet held an annual meeting of shareholders within twelve months of the Company’s fiscal year end and since the Nasdaq Hearings panel is currently considering the Company’s continued listing on based on another compliance matter, the Panel will include the Company’s annual meeting non-compliance as an additional basis for delisting. No annual meeting of stockholders was held in 2024 due primarily to t”

Wag! Group Co. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“January 14, 2025, Wag! Group Co. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for 30 consecutive business days from November 13, 2024 to January 13, 2025, the Company’s Market Value of Publicly Held Securities (“MVPHS”) was below the $15,000,000 required for continued listing on the Global Market (the “MVPHS Requirement”) under Nasdaq Listing Rule 5450(b)(2)(C). The notification has no immediate effect on the listing of the Company’s common stock and does not resu”

FutureTech II Acquisition Corp. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

“he “ Company ”) received a deficiency notification from the staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) for its failure to timely file with the SEC its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (“ 2024 3Q 10Q ”), in violation of Nasdaq Listing Rule 5250(c)(1) (the “ Periodic Filing Rule ”). On December 4, 2024, the Company requested the Staff to stay of suspension, pending a Hearings Panel decision and provide an additional time to allow the Company to regain compliance with Nasdaq. The hearing was held on December 17, 2024. On January 15, 202”

REPUBLIC AIRWAYS HOLDINGS INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“January 15, 2025, Mesa Air Group, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the period ended September 30, 2024 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The filing delay is not the result of a forthcoming restatement of the”

Aptose Biosciences Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last thirty (30) consecutive business days, the closing bid price for the Company’s common shares have been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company is required to present its plan of comp”

Aptose Biosciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“”

REPUBLIC AIRWAYS HOLDINGS INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“January 15, 2025, Mesa Air Group, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of th”

FutureTech II Acquisition Corp. received a nasdaq extension granted notice regarding late filing (rules 5250(c)(1)).

“January 15, 2024, the Company received a decision letter from the Hearing Panel of Nasdaq (the “ Panel ”) stating that it grants the Company’s request for continued listing on Nasdaq, provided that the Company files 2024”

Wag! Group Co. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“January 14, 2025, Wag! Group Co. (the “Company”) received a written notice from the staff (the “Staff”) of the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for 30 con”

Healthcare Triangle, Inc. received a nasdaq noncompliance notice notice regarding shareholders.

“January 14, 2025, Healthcare Triangle, Inc. (the “ Company ”), received a letter from Nasdaq (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rules since it has not yet held an annual meet”

GAN Ltd received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“January 14, 2025, GAN Limited (the “Company” ), received a written notice from The Nasdaq Stock Market LLC ( “Nasdaq” ) notifying the Company that it was not in compliance with the rules for continued listing as set fort”

NOCERA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“isting Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an”

T Stamp Inc received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 14, 2025, T Stamp Inc. (the “ Company ”) received a letter from The Nasdaq Stock Market LLC (“ Nasdaq ”), which stated that the Company no longer complies with Nasdaq’s continued listing rules due to the Company”

CIMG Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 14, 2025, CIMG Inc. (the “Company”) received a notification letter (the “Minimum Bid Price Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) indicating that the Company”

Pluri Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“epartment of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital”

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq hearing update notice regarding market value.

“January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On the same day, the Company received a letter from Nasdaq notifying the Company t”

Viracta Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)).

“January 13, 2025, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the previously disclosed resignation of Barry J. Simon, M.D. from the Company’s board of directors (the “Board”) and audit committee on December 18, 2024, the Company was no longer in compliance with Nasdaq’s audit committee requirements under Nasdaq Listing Rule 5605(c)(2). In accordance with Nasdaq Listing Rule 5605(c)(4), the Company has been provided a cure period to regai”

VivoSim Labs, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 16, 2025, the Staff provided a notice to the Company (the “Nasdaq Notice”) that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. The Nasdaq Notice further indicated that, unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company’s common stock would be subject to delisting. As a result, the Company intends to timely request a hearing. The hearing request will automatic”

AQUABOUNTY TECHNOLOGIES INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“Company that, for the last 32 consecutive business days, the closing bid price for its common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market or on the trading of the Common Stock, which continues to trade under the symbol “AQB”. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a c”

Sports Entertainment Gaming Global Corp received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 10, 2025, Lottery.com Inc. (the “Company” or the “Registrant”) received a written notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that the Company is no longer in compliance with Nasdaq Listing Rule 5620(a) due to its failure to hold an annual meeting of shareholders within twelve months from the end of the Company’s fiscal year 2023 (the “Annual Meeting Requirement”). The Company shall hold its 2024 Annual Meeting of its Stockholders on February 17, 2025, at 10:00 am (Central Time). SIGNATURES Pursuant to the r”